Raptor

Raptor is a biotechnology company in the development stage. The company is involved in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms using proprietary receptor-associated proteins and mesoderm development proteins to treat various brain disorders, neurodegenerative diseases, genetic conditions, and cancer. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trials for the treatment of nephropathic cystinosis (or cystinosis) and in Phase IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH).